About John Martin
John Martin led biotech firm Gilead Sciences for two decades as CEO through March 2016. He stepped down as chairman in March 2019.
His fortune comes from his shares of Gilead; he has sold most of his shares over the years and owns less than a 1% stake.
Martin, who has a PhD in organic chemistry, worked at Bristol Myers Squibb and Syntex before joining Gilead in 1990 as chief scientist.
Gilead made its mark with several antiviral drugs to treat HIV. It launched a Hepatitis C drug in 2014 that, while pricey, became a blockbuster.
Gilead acquired cancer drug firm Kite Pharma for $11.9 billion in October 2017.
Personal stats
Citizenship
United States of AmericaSource of wealth
pharmaceuticalsBirth date
05/07/51Number of children
2Self-made
self-madeJohn Martin’s fortune is worth
19K
troy ounces of gold
17K
median U.S. household
11K
median U.S. income
0.022%
U.S. credit card volume
0.004%
GDP of the United States
0.003%
United States debt
Net worth history
Annual ranking
Did you know?
Gilead was struggling and had 35 employees when Martin joined the company in 1990; it now has over 9,000 employees and $22 billion in revenues.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadNASDAQ | GILD-US
GileadImages © Forbes.com. All rights reserved.